Skip to main content
Premium Trial:

Request an Annual Quote

Protein Design Labs Licenses Resolver Gene Expression Analysis System from Rosetta

NEW YORK, July 11 – Protein Design Labs has agreed to license the Rosetta Resolver gene expression data analysis system from Rosetta Inpharmatics and exclusive distributor Agilent Technologies, the companies said Wednesday.

Financial details were not disclosed.

The Resolver system accepts data from a wide variety of expression profiling formats, including Affymetrix GeneChip and Agilent DNA microarrays, and applies proprietary error models to calculate statistics on gene expression data. Rosetta, based in Kirkland, Wash., released version 2.0 of the system in the first quarter of 2001.

Protein Design Labs, of Fremont, Calif., develops “humanized” monoclonal antibodies, mouse or rat antiobodies that are modified for therapeutic applications in humans. Max Vasquez, director of target validation at Protein Design Labs, said in a statement that the company would use the Resolver system in its antibody target identification and validation programs.

In May, Merck acquired Rosetta for $620 million in stock, but said that Rosetta would continue to operate the Resolver business as a separate cost center. Rosetta has licensed its Resolver system to a number of pharmaceutical and biotechnology companies, including GlaxoSmithKline, Biogen, Immunex, Paradigm Genetics, and Merck.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.